checkAd
    Startseite > Aktien > MediciNova > Nachrichten
    MediciNova Aktie
    1,3336
     
    USD
    -2,66 %
    -0,0364 USD
    Letzter Kurs 23:20:00 NYSE
    1,3000
     
    USD
    100 STK
    Geldkurs 22:02:00
    1,3600
     
    USD
    400 STK
    Briefkurs 22:02:00
    ISIN: US58468P2065 · WKN: A0LF3U · SYM: MNOV · USA

    Neueste Nachrichten

    MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
    05.06.24 · globenewswire · MediciNova
    MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
    03.06.24 · globenewswire · MediciNova
    MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
    28.05.24 · globenewswire · MediciNova
    MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
    20.05.24 · globenewswire · MediciNova
    MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
    14.05.24 · globenewswire · MediciNova
    MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
    07.05.24 · globenewswire · MediciNova
    MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
    03.04.24 · globenewswire · MediciNova
    MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
    27.03.24 · globenewswire · MediciNova
    MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
    21.03.24 · globenewswire · MediciNova
    MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
    12.03.24 · globenewswire · MediciNova
    MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
    17.01.24 · globenewswire · MediciNova
    MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
    22.12.23 · globenewswire · MediciNova